SLC5A2 and nervous system disorder: The lipid solubility and low molecular weights of SGLT2 inhibitors, in addition to the impaired integrity of blood brain barrier (BBB) in most endocrine and neurological disorders, support the notion that SGLT2 inhibitors may be able to penetrate BBB and exert their neuroprotective effects through SGLT2 that are highly expressed in the CNS (Pawlos et al. 2021).